全文获取类型
收费全文 | 5415篇 |
免费 | 369篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 46篇 |
儿科学 | 104篇 |
妇产科学 | 76篇 |
基础医学 | 622篇 |
口腔科学 | 65篇 |
临床医学 | 515篇 |
内科学 | 1455篇 |
皮肤病学 | 97篇 |
神经病学 | 716篇 |
特种医学 | 178篇 |
外科学 | 930篇 |
综合类 | 6篇 |
一般理论 | 1篇 |
预防医学 | 237篇 |
眼科学 | 58篇 |
药学 | 409篇 |
中国医学 | 8篇 |
肿瘤学 | 300篇 |
出版年
2024年 | 4篇 |
2023年 | 49篇 |
2022年 | 118篇 |
2021年 | 211篇 |
2020年 | 105篇 |
2019年 | 167篇 |
2018年 | 199篇 |
2017年 | 140篇 |
2016年 | 166篇 |
2015年 | 168篇 |
2014年 | 232篇 |
2013年 | 283篇 |
2012年 | 409篇 |
2011年 | 404篇 |
2010年 | 238篇 |
2009年 | 234篇 |
2008年 | 353篇 |
2007年 | 343篇 |
2006年 | 330篇 |
2005年 | 349篇 |
2004年 | 326篇 |
2003年 | 276篇 |
2002年 | 231篇 |
2001年 | 39篇 |
2000年 | 43篇 |
1999年 | 46篇 |
1998年 | 59篇 |
1997年 | 32篇 |
1996年 | 39篇 |
1995年 | 26篇 |
1994年 | 39篇 |
1993年 | 19篇 |
1992年 | 8篇 |
1991年 | 12篇 |
1990年 | 10篇 |
1989年 | 21篇 |
1988年 | 15篇 |
1987年 | 10篇 |
1986年 | 8篇 |
1985年 | 5篇 |
1984年 | 8篇 |
1983年 | 11篇 |
1982年 | 6篇 |
1980年 | 4篇 |
1979年 | 6篇 |
1976年 | 4篇 |
1975年 | 3篇 |
1971年 | 2篇 |
1970年 | 2篇 |
1968年 | 3篇 |
排序方式: 共有5823条查询结果,搜索用时 15 毫秒
101.
Eberspacher Chiara Ficuccilli Fabrizio Tessieri Laura D’Andrea Vito Lauro Augusto Fralleone Lisa Mascagni Domenico 《Digestive diseases and sciences》2021,66(11):3725-3729
Digestive Diseases and Sciences - Haemorrhoids, a common ailment afflicting mostly Western patients, can produce bothersome symptoms, in particular pain, pruritus, and bleeding. There is a wide... 相似文献
102.
Enrico Tincani Mark A Crowther Fabrizio Turrini Domenico Prisco 《Clinical Interventions in Aging》2007,2(2):237-246
Venous thromboembolism (VTE) is a common complication among hospitalized patients. Pharmacological thromboprophylaxis has emerged as the cornerstone for VTE prevention. As trials on thromboprophylaxis in medical patients have proven the efficacy of both low-molecular-weight heparins (LMWHs) and unfractionated heparin (UFH), all acutely medical ill patients should be considered for pharmacological thromboprophylaxis. Unlike in the surgical setting where the risk of associated VTE attributable to surgery is well recognized, and where widespread use of pharmacological thromboprophylaxis and early mobilization has resulted in significant reductions in the risk of VTE, appropriate VTE prophylaxis is under-used in medical patients. Many reasons for this under-use have been identified, including low perceived risk of VTE in medical patients, absence of optimal tools for risk assessment, heterogeneity of patients and their diseases, and fear of bleeding complications. A consistent group among hospitalized medical patients is composed of elderly patients with impaired renal function, a condition potentially associated with bleeding. How these patients should be managed is discussed in this review. Particular attention is devoted to LMWHs and fondaparinux and to measures to improve the safety and the efficacy of their use. 相似文献
103.
Fabrizio Tomai Achille Gaspardone Marco Papa Patrizio Polisca 《Catheterization and cardiovascular interventions》2002,55(1):97-99
We report a case of acute left ventricular failure after transcatheter closure of a single secundum atrial septal defect in a 68-year-old man with coronary artery disease. Just before the procedure, two coronary lesions had been treated with direct stenting. Transcatheter closure of atrial septal defects should always be deferred in ischemic heart disease patients who need percutaneous myocardial revascularization. 相似文献
104.
Broglio F Prodam F Gottero C Destefanis S Me E Riganti F Giordano R Picu A Balbo M Van der Lely AJ Ghigo E Arvat E 《Clinical endocrinology》2004,60(6):699-704
OBJECTIVE: Acylated ghrelin, a gastric peptide, possesses a potent GH- but also significant ACTH/cortisol-releasing activity mediated by the activation of GH secretagogue receptors (GHS-R) at the hypothalamus-pituitary level. The physiological role of ghrelin in the control of somatotroph and corticotroph function is, however, largely unclear. Glucagon is known to induce a clear increase of GH, ACTH and cortisol levels in humans, at least after intramuscular administration. In fact, glucagon is considered to be a classical alternative to insulin-induced hypoglycaemia (ITT) for the combined evaluation of the function of GH and the hypothalamus-pituitary-adrenal (HPA) axis. We aimed to clarify whether ghrelin mediate the GH and corticotroph responses to intramuscular glucagon or ITT, which has recently been reported able to induce a surprising ghrelin decrease. SUBJECTS: To this aim we enrolled six normal young male subjects [age (mean +/- SD): 29.0 +/- 8.0 years, body mass index (BMI) 21.9 +/- 2.5 kg/m(2)]. DESIGN AND MEASUREMENTS: In all the subjects we studied ghrelin, GH, ACTH, cortisol and glucose levels after glucagon (GLU; 0.017 mg/kg intramuscularly), ITT (0.1 IU/kg insulin intravenously) or saline administration. RESULTS: Saline infusion was not followed by any significant variation in ghrelin, GH and glucose levels while ACTH and cortisol showed the expected spontaneous morning trend toward a decrease. GLU administration increased (P < 0.01) circulating GH, ACTH and cortisol as well as insulin and glucose levels. ITT induced an obvious increase (P < 0.01) of GH, ACTH and cortisol levels. The ITT-induced increases in GH and ACTH, but not cortisol, levels were higher (P < 0.01) than those after GLU. Circulating ghrelin levels were not modified by GLU. On the other hand, ghrelin levels underwent a transient reduction (P < 0.01) after insulin-induced hypoglycaemia. CONCLUSIONS: Ghrelin does not mediate the GH and ACTH responses to glucagon or to the ITT. In fact, ghrelin levels are not modified at all by glucagon and transiently decrease during the ITT. These findings support the assumption that ghrelin does not play a major role in the physiological control of somatotroph and corticotroph function. 相似文献
105.
BACKGROUND/AIMS: The identification of metabolic and environmental predictors of excess body fat is still far from being achieved. The aim of this study was to evaluate whether respiratory quotient in non-obese women is a predictor of body weight changes after a 6-year follow-up period. METHODS: Forty-three non-obese healthy women participated in the study. Their baseline general characteristics were: age 40.5 +/- 12.8 years; height 159 +/- 7 cm; weight 61.8 +/- 10.1 kg, and body mass index (BMI) 24.4 +/- 3.8 kg/m2. At baseline basal metabolic rate and respiratory quotient were determined by indirect calorimetry, while weight and BMI were recorded at the first observation and after the 3- and 6-year follow-ups. RESULTS: At the first observation basal metabolic rate was 5,360 +/- 713 kJ/day and respiratory quotient 0.850 +/- 0.052. After 6 years, with weight changes equal to 1.4 +/- 4.5 kg, baseline respiratory quotient was a significant predictor (p < 0.05) of changes in body weight or BMI together with baseline BMI. CONCLUSIONS: This follow-up study confirms that a high respiratory quotient (measured on free diet) predisposes to weight gain, especially in women with the highest baseline respiratory quotient (above the 90th percentile of the distribution for this variable). 相似文献
106.
Sergio Raposeiras-Roubín Berenice Caneiro Queija Fabrizio D’Ascenzo Tim Kinnaird Albert Ariza-Solé Sergio Manzano-Fernández Christian Templin Lazar Velicki Ioanna Xanthopoulou Enrico Cerrato Giorgio Quadri Andrea Rognoni Giacome Boccuzzi Andrea Montabone Salma Taha Alessandro Durante Sebastiano Gili Giulia Magnani Emad Abu-Assi 《Revista espa?ola de cardiología》2019,72(3):215-223
Introduction and objectives
The PARIS score allows combined stratification of ischemic and hemorrhagic risk in patients with ischemic heart disease treated with coronary stenting and dual antiplatelet therapy (DAPT). Its usefulness in patients with acute coronary syndrome (ACS) treated with ticagrelor or prasugrel is unknown. We investigated this issue in an international registry.Methods
Retrospective multicenter study with voluntary participation of 11 centers in 6 European countries. We studied 4310 patients with ACS discharged with DAPT with ticagrelor or prasugrel. Ischemic events were defined as stent thrombosis or spontaneous myocardial infarction, and hemorrhagic events as BARC (Bleeding Academic Research Consortium) type 3 or 5 bleeding. Discrimination and calibration were calculated for both PARIS scores (PARISischemic and PARIShemorrhagic). The ischemic-hemorrhagic net benefit was obtained by the difference between the predicted probabilities of ischemic and bleeding events.Results
During a period of 17.2 ± 8.3 months, there were 80 ischemic events (1.9% per year) and 66 bleeding events (1.6% per year). PARISischemic and PARIShemorrhagic scores were associated with a risk of ischemic events (sHR, 1.27; 95%CI, 1.16-1.39) and bleeding events (sHR, 1.14; 95%CI, 1.01-1.30), respectively. The discrimination for ischemic events was modest (C index = 0.64) and was suboptimal for hemorrhagic events (C index = 0.56), whereas calibration was acceptable for both. The ischemic-hemorrhagic net benefit was negative (more hemorrhagic events) in patients at high hemorrhagic risk, and was positive (more ischemic events) in patients at high ischemic risk.Conclusions
In patients with ACS treated with DAPT with ticagrelor or prasugrel, the PARIS model helps to properly evaluate the ischemic-hemorrhagic risk. 相似文献107.
Carolina D’Anna Armando Caputi Benedetta Natali Benedetta Leonardi Aurelio Secinaro Gabriele Rinelli Alessia Del Pasqua Claudia Esposito Adriano Carotti Fabrizio Drago Marcello Chinali 《The international journal of cardiovascular imaging》2018,34(3):399-406
Right ventricular (RV) evaluation represents one of the major clinical tasks in the follow-up of repaired tetralogy of Fallot patients (rToF) with pulmonary valve regurgitation, as both severe RV dilatation and dysfunction are key factors in defining the need of pulmonary valve replacement. The aim of our study was to report the diagnostic accuracy of echocardiography in the identification of rToF patients with severely dilated and/or depressed RV as compared to cardiac magnetic resonance (CMR). Among our patients with rToF, a subgroup of 95 (17.6?±?6.8 years; 60% male), who underwent right ventricular qualitative and quantitative evaluation with CMR following echocardiographic suspicion of severe dilation/dysfunction, were included in the analysis. When comparing echocardiographic RV functional parameters to CMR findings, we found no association between CMR-ejection fraction (EF) and either tricuspid annulus plane systolic excursion (TAPSe) nor tissue Doppler systolic tricuspid excursion velocity (all p?=?ns). In contrast RVFAC was strongly associated with CMR-EF (r?=?0.44; p?<?0.01) as well as to longitudinal components of RV mechanics including tissue Doppler s′ (r?=?0.40; p?<?0.01) and TAPSE (r?=?0.36; p?<?0.01). When comparing echocardiographic and CMR structural parameters of the RV, we found that CMR RV volume was strongly related to echocardiographic measurements of RV end diastolic area (from the 4 chamber apical view) and with proximal parasternal short axis right ventricle outflow-dimension. Accordingly a regression model was derived from multiple regression analysis, which allows a more accurate estimate of CMR RV volume from echocardiography (r2?=?0.59, p?<?0.001). Our study demonstrates a significant, although imperfect, correlation between echocardiographic and CMR RV functional and geometrical parameters. Combining echocardiographic measures of RV inflow and RV outflow, we deliver a simple formula to estimate CMR-RV volume, improving the echocardiographic accuracy in RV volume quantification. 相似文献
108.
Theodore C. Bailey Maria W. Merritt Fabrizio Tediosi 《American journal of public health》2015,105(4):629-636
It has been suggested that initiatives to eradicate specific communicable diseases need to be informed by eradication investment cases to assess the feasibility, costs, and consequences of eradication compared with elimination or control.A methodological challenge of eradication investment cases is how to account for the ethical importance of the benefits, burdens, and distributions thereof that are salient in people’s experiences of the diseases and related interventions but are not assessed in traditional approaches to health and economic evaluation.We have offered a method of ethical analysis grounded in theories of social justice. We have described the method and its philosophical rationale and illustrated its use in application to eradication investment cases for lymphatic filariasis and onchocerciasis, 2 neglected tropical diseases that are candidates for eradication.The eradication of smallpox was a signature success of global public health in the 20th century, but it is an open and contentious question whether global eradication as opposed to regional elimination or control is warranted for other potentially eradicable infectious diseases.1–4 The box on page 630 provides our definitions of eradication, elimination, and control, as explained by Dowdle.4
Open in a separate windowSource. Dowdle.4Global eradication efforts require vast resource commitments that must be locked in over long time frames, thereby imposing opportunity costs that require justification. For example, donors invested $10.0 billion in the Global Polio Eradication Initiative from 1988 through 2012, and the Global Polio Eradication Initiative’s 2013 to 2018 strategic plan calls for an additional $5.5 billion, totaling $15.5 billion over 30 years.5 The Global Polio Eradication Initiative has prepared an economic case estimating net benefits to date at $27.0 billion and arguing that completion of the eradication initiative would be more cost effective than are available alternatives.6 Ideally, with so much at stake, deliberations about coordinated global approaches to eradicable infectious diseases should be informed by prospective comparative assessment of the feasibility, costs, and consequences of control, elimination, and eradication. The same point of principle applies to other large-scale, long-term, and resource-intensive health programs, substituting the relevant scenarios for comparison.The eradication investment case (EIC) framework is a method for making such assessments to apply them to eradicable infectious diseases.7–11 Although traditional health and economic assessments are core components of EICs, leading architects of the EIC framework contend that EICs should also include “a narrative of the moral value of launching an eradication program” to “capture the value of intangible benefits and ensure consideration of benefits that are difficult to quantify.”9(p143) EICs lacking such ethical analyses may critically overvalue or undervalue eradication scenarios compared with elimination or control by failing to identify ethically important kinds of benefits, burdens, and distributions thereof. The need for such prospective ethical analysis is not unique to assessing disease eradication programs and arguably should be part of assessing and justifying other kinds of health programs.How can EICs account for the ethical importance of the benefits, burdens, and distributions thereof that are salient in people’s experience of particular diseases and disease-related interventions but not assessed in traditional health and economic evaluations? We have proposed a method of ethical analysis grounded in social justice to help EICs respond to this challenge in hopes that it may also prove useful as an approach to prospective ethical assessment for health programs concerned with noneradicable infectious diseases and noninfectious diseases. We have illustrated the proposed method through its application to lymphatic filariasis and onchocerciasis, 2 neglected tropical diseases considered amenable to eradication and for which EICs are currently being assembled.7 相似文献
Definitions of Eradication, Elimination, and Control
Eradication—the permanent reduction to zero of the worldwide incidence of infection caused by a specific agent as a result of deliberate efforts so that intervention measures are no longer needed. |
Elimination—the reduction to zero of the incidence of infection caused by a specific agent in a defined geographical area as a result of deliberate efforts; continued measures to prevent reestablishment of transmission are required. |
Control—the reduction of disease incidence, prevalence, morbidity, or mortality to a locally acceptable level as a result of deliberate efforts; continued intervention measures are required to maintain the reduction. |
109.
110.